Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03531736
Recruitment Status : Recruiting
First Posted : May 22, 2018
Last Update Posted : February 12, 2020
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation described in the study is considered 'low intensity.' Although the chemotherapy agents used in this study and for transplant are FDA approved, the chemotherapy treatment and conditioning regimens or combinations listed in this consent are not yet FDA approved.

The CliniMACS device is FDA approved for one type of T cell depletion (positive selection of the stem cells) but not approved yet for other type of T cell depletion, which is being studied on this protocol. This pilot study, along with other studies will serve as the basis for FDA approval, if outcomes are favorable.


Condition or disease Intervention/treatment Phase
Myeloid Diseases Drug: Antithymocyte globulin (Rabbit) Drug: fludarabine Radiation: total body irradiation Drug: cyclophosphamide Drug: Rituxan Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is a pilot study to assess engraftment of a T cell depleted (TCD) graft following a reduced intensity conditioning regimen (RIC). The conditioning regimen will include total body irradiation (TBI), Fludarabine, anti-thymocyte globulin (ATG) and post transplant cyclophosphamide (PT-Cy). The graft will be TCD and will be composed of a TCR-α/β+ lymphocyte depletion stem cells and CD34+ selected stem cells.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Actual Study Start Date : May 9, 2018
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Patients with Myeloid Malignancies & Aplastic Anemia
Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
Drug: Antithymocyte globulin (Rabbit)
ATG (2 mg/kg/d IV on days-8 through -7)
Other Name: ATG

Drug: fludarabine
fludarabine (30 mg/m2/d on days -5 through -2)

Radiation: total body irradiation
TBI 200 cGy (days -2 and -1) given post stem cell infusion
Other Name: TBI

Drug: cyclophosphamide
cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)

Drug: Rituxan
Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia

Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation




Primary Outcome Measures :
  1. Rate of donor Neutrophil Engraftment [ Time Frame: 30 days post-transplant ]
    Neutrophil engraftment (recovery of ANC) defined by an ANC ≥ 500/mm^3 for 3 consecutive days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with one of the high risk myeloid diseases as outlined below. Patients must have ≤ 5% blasts on the last BM evaluation prior to starting the conditioning regimen. Diseases included on this protocol include:

    1. Acute Myeloid Leukemia (AML) in CR1 with intermediate or high risk features as defined below:

      °Cytogenetic abnormalities which are not considered "good risk" cytogenetic features (i.e t(8:21), t(15:17), inv 16 without c-kit mutations.

      And/or

      • Therapy related AML with history of antineoplastic therapy (radiation and/or chemotherapy) And/or
      • Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any others that are considered to be high risk
    2. AML in ≥ 2nd remission
    3. Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with:

      °International prognostic scoring system risk score INT-2 or high risk at the time of transplant evaluation.

      And/or

      • Any risk category if life-threatening cytopenia exists And/or
      • Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.
    4. Chronic myelomonocytic leukemia (CMML)
    5. Chronic myeloid leukemia (CML) with the following features:

      °Patients who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitors.

      And/or

      °CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g T351l mutation)

    6. Patients with severe aplastic anemia
  • Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria.
  • Non-Hodgkin lymphoma meeting both of the following criteria:

    • Responding to therapy prior to enrollment.
    • Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.
  • Multiple Myeloma with disease in the following categories:

    • Patients with relapsed multiple myeloma following autologous stem cell transplantation who have achieved at least partial response following additional chemotherapy
    • Patients with high risk cytogenetics at diagnosis must have achieved at least a partial response following autologous stem cell transplantation. Patients must have complex karyotype, del17p, t4;14, and/or t14;16 by FISH and/or del13 by karyotyping.
  • Each patient must be willing to participate as a research participant and must sign an informed consent form.
  • Organ Function and Performance Status Criteria:

    1. Patients be ≥ 18 years old.
    2. Patients must have a Karnofsky (adult) or Performance Status ≥ 70%.
    3. Patients must have adequate organ function measured by:

      • Cardiac: asymptomatic or if symptomatic, then LVEF at rest must be ≥ 40% and must improve with exercise.
      • Hepatic: < 5x ULN ALT and < 2x ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
      • Renal: CrCl >50ml/min (measured or calculated/estimated).
      • Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted (corrected for hemoglobin)

Exclusion Criteria:

  • Prior allogenic hematopoietic stem cell transplantation
  • Prior radiation therapy with 400cGY or more of TBI
  • BM with increased fibrosis (Reticulin stain > 1/3)
  • Active and uncontrolled infection at time of transplantation
  • HIV infection
  • Seropositivity for HTLV-1
  • Inadequate performance status/ organ function
  • Pregnancy or breast feeding
  • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.

Donor Inclusion and Exclusion Criteria:

  • Must be a 10/10 HLA genotypically match related or unrelated donor at all A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis
  • Able to provide informed consent for the donation process per institutional standards
  • Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03531736


Contacts
Layout table for location contacts
Contact: Roni Tamari, MD 212-639-5987 tamarir@mskcc.org
Contact: Miguel-Angel Perales, MD 212-639-8682

Locations
Layout table for location information
United States, New Jersey
Memoral Sloan Kettering Monmouth (Limited Protocol Activities) Recruiting
Middletown, New Jersey, United States, 07748
Contact: Roni Tamari, MD    212-639-5987      
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Roni Tamari, MD    212-639-5987      
Contact: Miguel-Angel Perales, MD    212-639-8682      
Principal Investigator: Roni Tamari, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Roni Tamari, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03531736    
Other Study ID Numbers: 17-639
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: February 12, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center:
Allogeneic Hematopoietic Stem Cell Transplantation
intensity conditioning regimen
17-639
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Aplastic
Anemia
Hematologic Diseases
Bone Marrow Diseases
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Antilymphocyte Serum
Thymoglobulin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Antineoplastic Agents, Immunological